Pfizer navigates post-pandemic era with innovation & restructuring
Overview
Pfizer reported strong financial results for both Q4 and full-year 2024, with revenues reaching $17.8bn in Q4 and $63.6bn for the full year. Excluding Paxlovid and Comirnaty, the company achieved 12% operational revenue growth in 2024. The company also reaffirmed its 2025 guidance, targeting revenues between $61bn and $64bn and adjusted diluted EPS of $2.80 – $3.00.
CEO Dr. Albert Bourla highlighted Pfizer’s strong execution, commercial expansion, and pipeline productivity, stating: “2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and financial commitments, strengthened our company and, most importantly, reached millions of patients with our medicines and vaccines. We made great progress with commercial execution and achieved growth across our product portfolio for full-year 2024. “I’m excited for what’s ahead and confident that we will enhance shareholder value as we sharpen our focus to improve the productivity of our R&D pipeline and advance the clear strategic priorities guiding our company in 2025.”
Q4 2024 vs. Q4 2023:
- Revenues increased to a value of $17.8bn (+22% YoY), driven by Seagen portfolio, Vyndaqel, and Eliquis.
- Biopharma Business had $17.4bn in revenue (+23% YoY), fueled by higher sales of Vyndaqel (+60% vs. 2023), Eliquis (+13% vs. 2023), and Xtandi (+24% vs. 2023).
- Seagen Portfolio contributed $915m in Q4 revenue (up from $132m in Q4 2023), following the acquisition.
- Paxlovid revenue had $727m in revenue (compared to a $3.1bn reversal in Q4 2023), due to the transition to commercial market sales in the U.S.
- Comirnaty (COVID-19 Vaccine) declined to a value of $3.4bn (-38% YoY), reflecting lower global demand.
- Nurtec ODT/Vydura experienced a 39% YoY growth due to strong U.S. demand and recent international launches.
- Xtandi revenue up 24% YoY, driven by expanded indications and affordability initiatives.
- Net income recorded a value of $410m, after a loss of $3.4bn recorded in the same period last year.
- Diluted EPS followed the same trend and reached a positive value of $0.07, after losing $0.60 in Q4 2023.
- R&D Investments increased 8% YoY in Q4, primarily for oncology and newly acquired products.
Full-Year 2024 highlights:
- Total revenues rose to $63.6bn (+7% YoY), with non-COVID products growing 12% operationally.
- Biopharma Business also had the same growth trend, reaching a value of $62.4bn (+7% vs. 2023).
- Net income experienced a significant increase, almost 4 times, reaching a value of $8.0bn (+279% YoY).
- Adjusted diluted EPS also recorded an increasing value of $3.11 (+69% vs. 2023).
- The company achieved $4bn in net cost savings in FY2024.
Pfizer expects full-year 2025 revenues to range between $61.0bn and $64.0bn, reflecting steady commercial execution and new product contributions. The company projects adjusted diluted EPS between $2.80 and $3.00, supported by cost realignment efforts targeting $4.5bn in total savings by year-end. Research & development expenses are estimated at $10.7bn – $11.7bn, focusing on pipeline productivity and next-generation therapeutics. The company also anticipates an adjusted SI&A expense range of $13.3bn to $14.3bn, ensuring operational efficiency while maintaining commercial momentum. With a 15% effective tax rate on adjusted income, Pfizer aims to optimize capital allocation, deleveraging, business development, and long-term shareholder returns.
After the announcement of the publication of the results, the price of PFE shares experienced a fluctuating trend, and overall, it experienced a decrease of over 3% in this trading week.
Author: Ionuț-Adrian Lazar
